Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus.
Macaluso FS, Caprioli F, Benedan L, Bezzio C, Caporali R, Cauli A, Chimenti MS, Ciccia F, D'Angelo S, Fantini MC, Festa S, Iannone F, Lubrano E, Mariani P, Papi C, Provenzano G, Pugliese D, Rispo A, Saibeni S, Salvarani C, Variola A, Zenga M, Armuzzi A, Orlando A, Gerli R. Macaluso FS, et al. Among authors: lubrano e. Autoimmun Rev. 2024 May;23(5):103533. doi: 10.1016/j.autrev.2024.103533. Epub 2024 Mar 22. Autoimmun Rev. 2024. PMID: 38521214 Free article. Review.
Aortic involvement in ankylosing spondylitis.
Palazzi C, D' Angelo S, Lubrano E, Olivieri I. Palazzi C, et al. Among authors: lubrano e. Clin Exp Rheumatol. 2008 May-Jun;26(3 Suppl 49):S131-4. Clin Exp Rheumatol. 2008. PMID: 18799070 Review.
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G. Spadaro A, et al. Among authors: lubrano e. Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11. Rheumatology (Oxford). 2010. PMID: 20223813
Emerging drugs for psoriatic arthritis.
Olivieri I, D'Angelo S, Palazzi C, Lubrano E, Leccese P. Olivieri I, et al. Among authors: lubrano e. Expert Opin Emerg Drugs. 2010 Sep;15(3):399-414. doi: 10.1517/14728214.2010.497139. Expert Opin Emerg Drugs. 2010. PMID: 20528612 Review.
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.
Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S, Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group. Cauli A, et al. Among authors: lubrano e. J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15. J Rheumatol. 2011. PMID: 21324965 Clinical Trial.
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.
Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, Matucci-Cerinic M, Olivieri I; Italian Society for Rheumatology. Salvarani C, et al. Among authors: lubrano e. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S28-41. Epub 2011 Jul 26. Clin Exp Rheumatol. 2011. PMID: 21906425 Review.
235 results